Corebridge Financial stock rating reiterated at Buy by TD Cowen

Corebridge and Equitable agreed a $22 billion all-stock merger that will leave Corebridge shareholders with ~51% of the combined company. Corebridge reported Q4 adjusted EPS $1.22 vs $1.11 consensus and revenue $6.34B vs $5.16B consensus, while shares are down 25% YTD and trading at $22.30 (52-week low $22.19) with RSI in oversold territory. TD Cowen reiterated a Buy with a $35 price target and sees long-term benefits from the deal; Evercore cut its target to $37 (from $38) but kept an Outperform rating, citing spread compression and expected Fed rate cuts in 2026; two directors resigned amid ownership changes.

Analysis

The merger creates an immediate capital-allocation inflection: near-term buyback demand will fall as capital is diverted to integration and potential balance-sheet reshaping, which removes a structural bid for the stock but simultaneously lowers operating leverage on EPS. That tradeoff creates a window for private-credit repricing to be reflected in marks — if manager-level NAVs are forced to revalue, the seller base could widen rapidly because a large portion of demand/patience was retail and buyback-driven. Expect realized credit shocks to show up unevenly across vintages and illiquid strategies, producing headline volatility long before fundamentals fully reprice.

Governance churn and a reduced anchor shareholder magnify merger execution risk: board turnover increases probability of deal hiccups, slower integration of distribution platforms, and potential management distraction. The largest macro swing is interest-rate direction: a more dovish Fed compresses spreads and reinvestment yields, which trims long-duration asset profitability for insurers over 6–24 months; the reverse magnifies reinvestment gains. Watch quarterly reserve actions and any pro forma capital tests — these are the highest-frequency catalysts for mark moves.

Given the mix of structural upside (scale, cross‑sell) and short-term execution/credit risk, the asymmetric opportunity is in controlled, idiosyncratic exposure with explicit hedges. The market appears to be treating credit concern and merger execution as largely priced — but not the timing disconnect between realized defaults and modelled stress (a months-to-years story). Our baseline is constructive conditional on steady credit trends and clean regulatory approval; adverse credit prints or a change in deal terms should flip the trade quickly.

Key Decisions for Investors

• Long CRBG equity as a 3–5% position sized for asymmetric payoff over 9–18 months; hedge ~35–50% of notional with a short EQH exposure (ratioed to remove market/merger beta). Target a 30–50% upside if integration runs to plan; use a 12–15% hard stop to limit downside in a realization-driven credit drawdown.
• Buy a 12–18 month CRBG call spread (long lower strike LEAP / short higher strike) sized 1–2% of portfolio to capture optionality while limiting premium outlay. This preserves upside to an orderly recovery while capping time decay; exit if company posts two consecutive quarter-on-quarter adverse reserve builds.
• Merger-pair trade: initiate a long CRBG / short EQH pair to isolate execution and credit idiosyncrasy (not market direction). Keep pair size small (1–3% net exposure) and unwind on any change to exchange mechanics, explicit regulatory objections, or if spread between the two moves >20% versus starting point.
• Hedge macro/credit tail risk by buying 3–9 month protection on corporate credit risk (e.g., HY puts or CDS) sized to offset 25–40% of portfolio exposure to private-credit repricing. Close hedge when private-credit markdowns stabilize across two consecutive reporting cycles or when rate-cut guidance materially changes.